Incyte net worth
Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix) , Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib). In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta. WebApr 5, 2024 · Incyte had a net margin of 10.03% and a return on equity of 11.45%. The company had revenue of $926.70 million for the quarter, compared to analyst estimates of $880.25 million. During the same quarter last year, the business earned ($0.07) earnings per share. ... At 3x Earnings, Avis Budget Is Worth Taking for a Spin; Toyota Is The Reliable ...
Incyte net worth
Did you know?
WebApr 11, 2024 · Exchange Traded Concepts LLC’s holdings in Incyte were worth $2,031,000 at the end of the most recent reporting period. A number of other hedge funds have also made changes to their positions... WebInteractive chart of historical net worth (market cap) for Incyte (INCY) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the …
WebJan 25, 2024 · The estimated Net Worth of Corp Incyte is at least $310 Million dollars as of 16 June 2024. Corp Incyte owns over 214,000 units of Merus N.V stock worth over $307,380,450 and over the last 6 years Corp sold MRUS stock worth over $2,883,520. Wallmine is a radically better financial terminal. WebJan 24, 2024 · The current estimated net worth of Incyte Corp's Principal Accounting Officer, Thomas Tray, is estimated to be about $1.71M . Thomas Tray owns about 16,606 units of Incyte Corp common stock. In ...
WebFeb 7, 2024 · – Jakafi ® (ruxolitinib) net revenues of $647 million (+9% Y/Y) in Q4'22 and $2.41 billion (+13%) in FY'22; Jakafi net revenues guidance range of $2.53 - $2.63 billion for FY 2024 – Opzelura™ (ruxolitinib) Cream net revenues of $61 million in Q4'22 and $129 million in FY'22, driven by strong demand in atopic dermatitis, a successful ... WebApr 15, 2024 · Incyte accounts for approximately 5.7% of International Biotechnology Trust PLC's holdings, making the stock its 3rd biggest holding. International Biotechnology …
WebJan 26, 2024 · Hedge Fund. Julian Baker has had an illustrious career in the business of trading and investing in the fields of health, global education, and youth. Baker graduated from Harvard with an A.B in Social Studies in the 1980’s. From 1988 to 1993 he worked at the private equity investment arm of Credit Suisse First Boston.
WebIncyte net worth Mar, 2024 Incyte net worth 2.21 Million Millions of dollars 84% Net worth score Disclamer: Incyte net worth displayed here are calculated based on a combination social factors. Please only use it for a guidance and Incyte's actual income may vary a lot from the dollar amount shown above. Wanna follow Incyte's net worth? raymond james stock price todayWebJan 24, 2024 · The current estimated net worth of Incyte Corp's Chairman / CEO, Herve Hoppenot, is estimated to be about $45.23M . Herve Hoppenot owns about 350,465 units of Incyte Corp common stock. In... simplified baseWebMar 21, 2024 · Incyte has 5 employees across 12 locations and $3.39 b in annual revenue in FY 2024. See insights on Incyte including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. ... Net income (FY, 2024)$340.7M Cash (FY, 2024)$3.0B EBIT (FY, 2024)$579.4M Enterprise value $13.4B. Competitors and similar ... simplified bas formWebJan 25, 2024 · The estimated Net Worth of Corp Incyte is at least $310 Million dollars as of 16 June 2024. Corp Incyte owns over 214,000 units of Merus N.V stock worth over … raymond james structured notesWebApr 4, 2024 · The current estimated net worth of Incyte Corp's Director, Felix Baker, is estimated to be about $20.02B . Felix Baker owns about 33,452,465 units of Incyte Corp common stock. In the last... simplified base shearWebMar 20, 2024 · Incyte had a net margin of 10.03% and a return on equity of 11.45%. The firm had revenue of $926.70 million for the quarter, compared to the consensus estimate of $880.25 million. raymond james st petersburg fl new hiresWebApr 13, 2024 · Should you invest in Incyte (Nasdaq:INCY)? Flawless balance sheet with high growth potential. ... Executive VP & Chief Scientific Officer exercised options to buy US$287k worth of stock. Feb 23. Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa ... Incyte Q2 results ... simplified bas reporting